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A Commentary on
Distribution of 5-HT1F Receptors in Monkey Vestibular and Trigeminal Ganglion Cells
by Usman HO, Balaban CD. Front Neurol (2016) 7:173. doi: 10.3389/fneur.2016.00173
Based on the assumption that a congruence exists between the expression of serotonin (5-hydroxy-
tryptamine, 5-HT) receptors and vestibular pathways, Usman and Balaban (1) showed the distribu-
tion of 5-HT1F receptors in vestibular and trigeminal ganglia, including blood vessels, in the monkey. 
They also discussed the relationship between the 5-HT1F receptor and 5-HT1B and 5-HT1D receptors, 
using previously data from their laboratory. They logically explain possible interactions of triptans 
on 5-HT1F receptors (triptans also activate 5-HT1B and 5-HT1D receptors) and also point out that 
serotonin may be involved in the pathophysiology of some migrainous features (e.g., tinnitus and 
phonophobia) in vestibular migraine.
In the central nervous system (CNS), serotonin neurons are involved in functions such as appetite, 
sleep, mood, thermoregulation, anxiety, aggression, learning and cognition, also inducing feelings of 
well-being and happiness. Serotonin is also an important vasoconstrictor, which may account for the 
vasomotor changes observed during a migraine attack.
Serotonin, a monoamine neurotransmitter, is encountered in significant quantities in the CNS 
and gastrointestinal tract. Nausea and vomiting are pathognomonic features of a migraine attack, 
and serotonin agonists may be a strong vomiting and nausea trigger. Furthermore, reduction in brain 
synthesis of serotonin by tryptophan depletion was able to provoke more intense headache, nausea, 
and photophobia in migraine patients (2).
In vestibular migraine, the balance disorder is often associated with nausea and vomiting, again 
pointing to the pivotal role of the central serotonergic system in the pathophysiology of migraine (3).
The evolutionary role of serotonin in feeding, i.e., food selection and absorption, must have 
occurred. Particular types of food or beverage may trigger migraine attacks (4–7). In contrast, 
attacks are also provoked by fasting (8). Poisonous or toxic food is eliminated by induced vomiting 
or diarrhea through a serotonergic mechanism. Curiously, on the phylogenetic scale, serotonin may 
be found in fungi and plants (9). Plant spines and some venoms secreted by insects may contain 
serotonin, which causes pain in the threatening animal to ward off the danger. This also shows its 
important role in self-defense and induction of pain, even in primitive forms of life.
Serotonin is also encountered in some seeds and fruits, helping the digestive function. Ninety 
percent of the serotonin of the body is located in the gastrointestinal tract (enterochromaffin cells), 
whose function is to regulate gastrointestinal mobility, fundamental in food absorption. There is a 
bidirectional communication between gut and CNS. The gut transmits information to CNS through 
multiple forms, including vagal and spinal neurons, and gut receives CNS outputs by autonomic 
neurons and neuroendocrine regulation (10).
FiGure 1 | the role of serotonin in migraine physiopathogenesis, 
phylogenetic scale, human evolution, and drug development.
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An evolutionary role of migraine in guaranteeing survival and 
successful reproduction was described (11). Migraine probably 
exerted a role in the organization of the world’s first cities, trans-
forming a previously nomadic existence into a sedentary way 
of life (12). Conditions such as incapacitating migraine attacks, 
pregnancy, lactation, and menses may well be states that led our 
species to its present-day “civilized” way of life (12).
Some individuals present a worsening in their migraine 
attacks when changes in the environment occur, e.g., emotional 
or physical stress. Regarding feeding, distinct smells, specific food 
ingestion, and food privation might all have triggered migraines 
in these migraine-prone individuals who, by changing their 
behavior, may have forced the entire group to reconsider their 
previous migratory way of life (12).
My main comment on serotonin and its relation to vomit-
ing is that, since the time of Hippocrates, it has been known 
that, in some individuals suffering a migraine attack, the crisis 
is completely relieved after an episode of vomiting (13). Some 
migraineurs, on realizing that an episode of vomiting can stop 
a migraine attack, induce vomiting in order to curtail the attack 
(14–16). In some series, up to 15% of the migraineurs reported 
using induced vomiting in an attempt to bring to an end a 
migraine crisis (14–16).
The question still to be answered is: why does this occur? 
Interestingly, to date, no drug has been able to provide immedi-
ate relief of the migraine pain. The good therapeutic response 
expected with the use of analgesic and migraine-specific drugs 
is a progressive decrease in the pain intensity lasting up to 2 h in 
migraineurs. In this context, Chai and coworkers (10) recently 
discussed some hypotheses for how vomiting could stop migraine 
attacks.
Serotonin antagonists have largely been used as antiemetic 
drugs, particularly 5-HT3 receptor antagonist (17), but their 
effects on the pain are weak or non-existent. There is clearly a 
myriad of different serotonin receptor subtypes, each of which has 
a particular function depending on the neuronal system where 
it is located and on the various inputs that may influence the 
neuronal response. The chemoreceptor trigger zone in the area 
postrema, a brain structure that acts as a vomit-inducing center 
in the medulla, has different subtypes of serotonin receptors 
and, due to the absence of the blood–brain barrier, circulating 
substances in the blood or cerebrospinal fluid may either inhibit 
or stimulate the mechanism of vomiting.
Over the past few decades, a number of drugs that act on sero-
tonin receptors or by regulating the serotonin concentration in 
synapses have been developed and introduced in clinical practice, 
both to treat acute headache attacks and to preventively control 
incapacitating crises in a migraineur.
Interestingly, serotonin-modulating drugs such as reuptake 
inhibitors (e.g., fluoxetine and citalopram) have no clear efficacy 
for migraine prevention but also do not seem to make migraine 
attacks any worse. The marginal beneficial effects (18–21), if 
any, on the migrainous features claimed by some, may also be 
due to control of the depressive and anxiety symptoms by these 
antidepressants/anxiolytics drugs, depression and anxiety being 
comorbidities, which might influence the frequency of migraine 
attacks (21, 22).
Even now, with all the information available on serotonin 
and its receptors, we are still far from elucidating the mechanism 
involved in a migraine attack. Thus, studies such as this (1) are 
essential for understanding the pathogenesis of migraine and 
planning a rational form of treatment (23). Understanding the 
mechanism through which vomiting may interrupt a migraine 
attack may also help in the development of new drugs with a more 
effective action in interrupting migraine attacks more swiftly (see 
Figure 1).
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